Mini-Crush Versus T-Provisional Techniques in Bifurcation Lesions Clinical and Angiographic Long-Term Outcome After Implantation of Drug-Eluting Stents by Galassi, Alfredo R. et al.
CM
i
C
o
A
D
C
C
O
c
n
B
s
d
d
M
t
1
2
R
s
n
[
t
(
C
p
n
a
b
C
F
o
M
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 2 , N O . 3 , 2 0 0 9
© 2 0 0 9 B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 1 9 3 6 - 8 7 9 8 / 0 9 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . D O I : 1 0 . 1 0 1 6 / j . j c i n . 2 0 0 8 . 1 2 . 0 0 5LINICAL RESEARCH
ini-Crush Versus T-Provisional Techniques
n Bifurcation Lesions
linical and Angiographic Long-Term Outcome After Implantation
f Drug-Eluting Stents
lfredo R. Galassi, MD, FACC, FSCAI, FESC, Salvatore D. Tomasello, MD,
avide Capodanno, MD, Giovambattista Barrano, MD, Gian Paolo Ussia, MD, FSCAI,
orrado Tamburino, MD, FSCAI, FESC
atania, Italy
bjectives This retrospective study sought to assess the clinical and angiographic long-term out-
ome after implanting drug-eluting stents in bifurcation lesions with the T-provisional (T-prov) tech-
ique and mini-crush (MC) technique.
ackground The best option on the treatment of coronary bifurcation lesions is a subject of con-
iderable debate. However, recent evidence suggests that bifurcation lesions might be treated by
rug-eluting stent on both branches using the MC technique with a low rate of major adverse car-
iac event and restenosis.
ethods From April 2004 to July 2006, 457 patients were consecutively treated with either MC
echnique (n  199) or T-prov technique (n  258). Of these latter, 170 patients were treated with
stent and 88 patients with 2 stents. The 9-month angiographic follow-up was completed in 188 of
29 (82.1%) bifurcation lesions of MC patients and in 207 of 266 lesions (77.8%) of T-prov patients.
esults After a propensity score adjustment, 2-year cumulative major adverse cardiac events were
imilar between groups (p  0.16). The MC group compared with the T-prov 1-stent group had sig-
iﬁcantly lower main and side branches restenosis (hazard ratio [HR]: 0.52, 95% conﬁdence interval
CI]: 0.27 to 0.99; p  0.047; and HR: 0.41, 95% CI: 0.20 to 0.85; p  0.016, respectively). However,
he MC group compared with the T-prov-only group had signiﬁcantly lower side branch restenosis
HR: 0.55, 95% CI: 0.37 to 0.82; p  0.004).
onclusions Both techniques of bifurcation treatment met high procedural success with low com-
lication rates and similar major adverse cardiac event long-term outcome. However, the MC tech-
ique yields a lower restenosis rate at both main and side branches. These results may conﬁrm the
dvantage of using prescheduled 2-stent technique to give a complete coverage of the side
ranches’ ostium. (J Am Coll Cardiol Intv 2009;2:185–94) © 2009 by the American College of
ardiology Foundation
rom the Department of Internal Medicine and Systemic Disease, Clinical Division of Cardiology, Ferrarotto Hospital, University
f Catania, Catania, Italy.anuscript received April 17, 2008; revised manuscript received November 24, 2008, accepted December 17, 2008.
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186reatment of bifurcation lesions remains a technical
hallenge for the interventionalist, but it is still hampered
y an increased rate of restenosis as compared with non-
ifurcation lesions (1–3). Part of this treatment complexity
s related to the different anatomic patterns of the stenosis,
onsidering the possible involvement with the proximal and
he distal part of the main branch and/or the side branches,
nd the close proximity of side branches origins (4), besides
he angle that the side branch takes off and the size of both
ain and side branches. Various studies on the drug-eluting
See page 195
tent era indicate the absence of a real advantage over
estenosis considering the potential for both early proce-
ural complications (stent distortion, plaque shift, dissec-
ion, side branching trapping) and late in-stent restenosis
hen using a complex strategy (5–8). Indeed, anatomical
characteristics of bifurcation le-
sion may influence the treatment
strategy, choosing between 1-
and 2-stent approaches.
More recently further refine-
ments of the 2-stent technique
(9 –11) have shown that the
2-stent strategy technique, when
appropriately performed, may sig-
nificantly reduce the restenosis
rate and potentially target lesion
revascularization (TLR) and ma-
jor adverse cardiac event (MACE)
in complex bifurcation lesions.
This study aims to compare the
long-term clinical and angio-
graphic outcomes after implanting
he drug-eluting stent in bifurcations lesions using the mini-
rush (MC) and T-provisional (T-prov) techniques.
aterials and Methods
tudy population. The ethics committee approved the pro-
ocol, and all patients gave written informed consent.
emographic and procedural data regarding all patients
ndergoing angioplasty with drug-eluting stents—either
irolimus-eluting (Cypher/Cypher Select, Cordis Johnson
Johnson, Warren, New Jersey) or paclitaxel-eluting
Taxus Liberte, Boston Scientific, Natick, Massachusetts)—
ere prospectively put into a dedicated database.
Between April 2004 and July 2006, 3,480 patients un-
erwent a percutaneous coronary intervention in our insti-
ution. Among them, 544 patients (16%) had de novo
ifurcation lesions excluding left main trunk location, with
visually estimated percent diameter stenosis 50% involv-
bbreviations
nd Acronyms
MI  acute myocardial
nfarction
I  confidence interval
R  hazard ratio
ACE  major adverse
ardiac event
C  mini-crush
BR  target bifurcation
evascularization
LR  target lesion
evascularization
-prov  T-provisional
tentingng the main vessel at or within 5 mm proximal or distal to khe origin of a side branch 2 mm in diameter (12). All
ifurcation lesions were classified by visual assessment
ccording to a classification previously described by Medina
t al. (12). The MC technique was performed in 199
atients (this group included 45 patients from a previous
ilot study); T-prov in 170 patients with a single stent in the
ain vessel across the origin of the side branch (T-prov
-stent); T-prov in the other 88 patients where an addi-
ional stent was required in the side branch because of the
resence of severe impairment in the side branch during the
ngioplasty procedure (dissection or severe ostial stenosis
ue to plaque shift) (T-prov 2-stent). Other different
echniques such as crush, culotte, and V-stenting were used
n 87 patients. The bifurcation treatment strategy was chosen
ccording to the operator’s personal experience and prefer-
nces. All consecutive patients with a bifurcation lesion treated
ith either sirolimus- or paclitaxel-eluting stents by the MC or
y a T-prov stenting technique with and without the addi-
ional implantation of a side branch stent were retrospectively
dentified in the operator’s reports and checked through an
ndependent review of all angiograms.
ngioplasty procedure. All patients were previously treated
ith aspirin 100 mg and either ticlopidine or clopidogrel. A
00-mg loading dose of clopidogrel before the index pro-
edure was administered if patients were not pretreated.
uring the procedure, patients received intravenous unfrac-
ionated heparin (80 IU/kg) to maintain activated clotting
ime between 250 and 300 s. The administration of glyco-
rotein IIb/IIIa inhibitors was left to the operator’s discre-
ion. After the procedure, all patients were prescribed
spirin (100 mg daily) and clopidogrel (75 mg daily) or
iclopidine (500 mg daily) to be continued for at least 9
onths after drug-eluting stent implantation. The MC and
-prov techniques have been previously described (9–13).
riefly, the MC technique as compared with the standard
rush approach consisted of a minor retraction of the side
ranch stent into the main branch and using a balloon to
rush the side branch stent instead of the main branch stent.
ollowing this approach, a jailed wire technique and final
issing balloon would have been employed if possible, using
ire recrossing into the side branch followed by high-
ressure balloon inflation. As regards the T-prov approach,
alloon dilatation of the side branch or kissing balloon were
ecommended before stent deployment in the parent vessel.
he side branch was then rewired, and the balloon dilata-
ion of the ostium was repeated across the metal structure of
he stent; patients treated with this kind of approach were
ncluded in the T-prov 1-stent group. Stenting of the side
ranch origin was considered in the presence of a residual
tenosis 50% or coronary Thrombolysis In Myocardial
nfarction (TIMI) flow grade 3; patients treated with this
pproach were included in the T-prov 2-stent group.
onsistent with the standard of care in our laboratory, final
issing balloon inflation was recommended in all patients.
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187All patients were monitored for any post-procedure
vents of chest pain, heart failure, bleeding, or any ischemic
vents. Creatine kinase-myocardial band and troponin I
ere measured at 6 to 8 and 12 to 24 h post-procedure.
linical deﬁnition and follow-up. Clinical follow-up was
erformed by office visit or by telephone interviews at 1
onth, 6 months, 1 year, and 3 years. All events were
onfirmed by review of death certificates and hospital charts.
tress test or functional imaging test were recommended to
e performed between 5 and 6 months, after the procedure
or all patients. Angiographic follow-up was recommended
s a laboratory standard of care, to be performed approxi-
ately at 9 months after the procedure unless indicated
arlier by clinical suspicion or positive functional imaging
est.
Major adverse cardiac events were defined as cardiac
eath, acute myocardial infarction (AMI), and target vessel
evascularization, either percutaneous or surgical. All deaths
ere considered cardiac in origin unless alternatively docu-
ented. A non–Q-wave AMI was defined as creatine
inase-myocardial band enzyme elevation 3 times the
pper limit of the normal value; when in addition to enzyme
levation there were new pathological Q waves in the
lectrocardiogram, the event was defined as a Q-wave AMI.
eintervention for restenosis was decided by taking into
onsideration the patient’s symptoms, functional imaging
esting, and angiographic findings. Target lesion revascular-
zation was defined as a repeat revascularization with a
tenosis 50% within the stent or in the 5-mm distal or
roximal segments adjacent to the stent. Target vessel
evascularization was defined as repeat revascularization
ithin the treated vessel. Target bifurcation revasculariza-
ion (TBR) was defined as a repeat revascularization with a
tenosis 50% within 5 mm proximal or distal to the carina
f bifurcation, both onto the main branch and/or side
ranch as previously described (9).
Stent thrombosis was defined as an acute coronary syn-
rome with angiographic documentation of either vessel
cclusion or thrombus within or adjacent to a previously
uccessful stented vessel or, in the absence of angiographic
onfirmation, either AMI in the distribution of the treated
essel or death not clearly attributable to any other causes
14). Stent thromboses were categorized according to the
iming of the event into intraprocedural, subacute throm-
osis (from the end of the procedure to 30 days), and late
tent thrombosis (30 days).
uantitative coronary angiographic analysis. Coronary an-
iograms obtained at baseline, at completion of the stenting
rocedure, and at 9.6  4.3 months for MC-treated
atients, at 10.4  3.7 months for T-prov 1-stent treated
atients, and at 10.8  5.6 months of T-prov 2-stent–
reated patients (analysis of variance) (p  0.147) were
nalyzed using CardiOp-B, a computer-based algorithm
-dimensional reconstruction dedicated to bifurcations SPaieon Medical Ltd., Park Afek, Israel) (15). This system
ntegrates information from at least 2 single-plane angio-
raphic images taken from different angles of projection.
ne experienced technician who was blinded to patients’
dentities, outcomes, and sequence of the film, performed
uantitative analyses of all angiographic data. Minimal
umen diameter and the nearest normal reference diameter
ere measured in millimeters using the catheter as a scaling
actor. Percent stenosis was calculated as: 100 (1  minimal
umen diameter/normal reference diameter). Binary angio-
raphic restenosis was defined as50% diameter stenosis of
he target lesion. Late lumen loss was defined as the
ifference in minimal luminal diameter at completion of the
tent procedure and during follow-up. Quantitative angio-
raphic measurements of the target lesion were made at the
in-stent” zone (only the stented segment) and at the
in-segment” zone (stented segment and margins 5 mm
roximal and distal to the stent). Angiographic success was
efined as a final residual stenosis 30% with TIMI flow
rade 3 in either the main branch or the side branch (16).
rocedural success was defined as the achievement of
ngiographic success without in-hospital MACE. In pa-
ients who had restenosis, the pattern of restenosis was
ssessed according to the classification of Mehran et al. (17).
ach patient’s baseline, post-procedure, and follow-up cor-
nary angiograms were analyzed. Patients for whom 1 of the
ngiograms was unreadable were cut out of the analysis: 15
rom the MC group, 12 from the T-prov 1-stent group, and
from the T-prov 2-stent group. A total of 188 lesions out
f 229 (82.1%) in 160 patients were analyzed for the MC
roup, 138 lesions out of 176 lesions (78.4%) in 132 patients
ere analyzed for the T-prov 1-stent group, and 69 lesions
ut of 90 lesions (76.7%) in 69 patients were analyzed for
he T-prov 2-stent group
tatistical analysis. Continuous variables were presented as
ean  SD and were compared using Student unpaired t
est or analysis of variance. Categorical variables were
resented as counts and percentages and compared with the
hi-square test when appropriate (expected frequency 5).
therwise, the Fisher exact test was used. A 2-sided p value
f 0.05 was considered to indicate statistical significance.
Propensity score was used to create a covariate that
ummarizes confounders within baseline demographic and
ngiographic characteristics and assesses the independent
ffect of treatment technique on all outcome measures. For
ach considered comparison (MC vs. T-prov 1-stent and
C vs. T-prov) a separate propensity score was derived.
he details of the propensity-score method, with the
esulting models and their predictive characteristics, are
escribed in the Online Appendix. Calibration of the
ropensity score model was assessed using the Hosmer-
emeshow test.
All data were processed using the Statistical Package forocial Sciences, version 15 (SPSS Inc., Chicago, Illinois).
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188esults
aseline and procedural characteristics. Baseline clinical
haracteristics are shown in Table 1 among the 3 groups of
he patients. Table 2 shows the angiographic locations and
ypes of treated bifurcation lesions. It is interesting to note
hat type 1,1,1 bifurcation was present in the great majority
f cases in all the groups of patients and as type 1,1,1 more
requently in MC groups than in T-prov groups. Procedural
etails are shown in Table 3.
Clinical and angiographic outcomes are shown in Table
. A higher rate of hospital MACE albeit small was shown
n both T-prov groups of patients, which may be explained
y the higher rates of unstable angina as clinical presenta-
ion in this cohort of patients. Successful delivery of stent to
oth main and side branch, in the case of MC was
ccomplished adequately in each case. An additional stent in
he main branch to cover the full lesion length or to seal
ignificant dissections at edges of study stent was required in
8 of 229 lesions (25.3%) in the MC group, in 58 of 176
esions (32.9%) in the T-prov 1-stent group, and in 15 of 90
esions (16.6%) in the T-prov 2-stent group. Two additional
tents in the main vessel were implanted in 10 out of 229
esions (4.4%) in the MC group, in 4 out of 176 lesions
2.3%) in the T-prov 1-stent group, and in 3 out of 90
esions (3.3%) in the T-prov 2-stent group. An additional
tent in the side branch was required in 8 of 229 (3.5%) in
Table 1. Baseline Clinical Characteristics
Mini-Crush
(n  199 Patients) (n 
Age, yrs 62.17  9.65 64
Male 167 (83.9)
Hypertension 104 (52.3)
Hypercholesterolemia 121 (60.8)
Family history of CAD 93 (46.7)
Current smokers 126 (63.3)
Diabetes mellitus 61 (30.7)
Prior CABG 8 (4)
Prior MI 50 (25.1)
LVEF 50.9  9.2
Clinical presentation
Asymptomatic 16 (8)
Stable angina 68 (34.2)
Unstable angina 55 (27.6)
Acute MI 60 (30.2)
1-vessel 50 (25.1)
2-vessel 72 (36.2)
3-vessel 77 (38.7)
Values are presented as mean SD or n (%). *p 0.05 for MC versus T-prov; †p 0.05 for MC versu
versus T-prov 2-stent; ¶p 0.05 for T-prov 1-stent versus T-prov 2-stent; #p 0.001 for MC versusCABG coronary artery bypass graft; CAD coronary artery disease; LVEF left ventricular ejection frahe MC group, but in only 1 case (1.1%) in the T-prov
-stent group. Stress test or functional imaging test were
erformed in 96% of MC patients, in 93% of T-prov 1-stent
atients, and in 92% of T-prov 2-stent patients.
The 9-month angiographic follow-up was completed in
88 of 229 (82.1%) bifurcation lesions of MC patients, in
38 of 176 (78.4%) lesions of T-prov 1-stent patients, and
n 69 of 90 (76.7%) lesions of T-prov 2-stent patients.
ngiographic quantitative coronary angiography results for
oth the main and the side branch at baseline, after
rocedure, and at follow-up are summarized in Table 5.
Clinical follow-up was available for all patients at 752 445
ays (25  15 months). Based on the average follow-up time,
o significant differences were observed among the groups.
umulative MACE at follow-up was similar between MC and
oth T-prov patient groups (20.6% vs. 25.9% vs. 26.1%, p 
S among all 3 groups) and TLR (16% vs. 20.3% vs. 26.1%,
NS among all 3 groups). However, it is interesting to note
hat TBR was significantly lower in MC patients as compared
ith T-prov 2-stent patients (8.5% vs. 17.4%, p  0.05). The
C group compared with both T-prov groups showed a
imilar main branch restenosis (11.7% vs. 17.4% vs. 18.6%, p
S among all 3 groups) but significantly lower side branch
estenosis (8.5% vs. 18.8% vs. 25.7%, p  0.01 of MC vs.
-prov 1-stent and p  0.001 of MC vs. T-prov 2-stent,
espectively). There were 37 focal restenosis at the ostium of
ide branch, 6 in the MC group, 17 in the T-prov 1-stent
T-Prov
all
atients)
1-Stent
(n  170 Patients)
2-Stent
(n  88 Patients)
10.41* 63.88  10.61 65.20  10.00†
.9)‡ 122 (71.8)§ 66 (75.0)
.8)‡ 114 (67.1)§ 61 (69.3)
.3) 108 (63.5) 45 (51.1)
.5) 92 (54.1) 46 (52.3)
.3) 100 (58.8) 40 (45.5)¶
.3) 56 (32.9) 30 (34.1)
6) 14 (8.2) 3 (3.4)
.8)‡ 64 (37.6)§ 31 (35.2)
10.2 49.9  10.2 49.310.2
1) 12 (7.1) 9 (10.2)
.0)# 36 (21.2)§ 13 (14.8)*
.8)# 68 (40.0)§ 45 (51.1)**
.1) 54 (31.8) 21 (23.9)
.7) 52 (30.6) 17 (19.3)
.7) 54 (31.8) 33 (37.5)
.5) 64 (37.6) 38 (43.2)
v 2-stent; ‡p 0.01 for MC versus T-prov; §p 0.01 for MC versus T-prov 1-stent; p 0.01 for MC
; **p 0.001 for MC versus T-prov 2-stent.Over
258 P
.33 
188 (72
175 (67
153 (59
138 (53
140 (54
86 (33
17 (6.
95 (36
49.7
21 (8.
49 (19
113 (43
75 (29
69 (26
87 (33
102 (39
s T-pro
T-provction; MCmini-crush; MImyocardial infarction; T-prov T-provisional.
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189Table 2. Baseline Lesion Characteristics
Mini-Crush
(n  229 Lesions)
T-Prov
Overall
(n  266 Lesions)
1-Stent
(n  176 Lesions)
2-Stent
(n  90 Lesions)
Lesion location
LAD/DB 175 (76.4) 191 (71.8) 126 (71.6) 65 (72.2)
LCX/OM 48 (21) 63 (23.7) 40 (22.7) 23 (25.6)
RCA/PL 6 (2.6) 12 (4.5) 10 (5.7) 2 (2.2)
Bifurcation type (Medina classiﬁcation)
Type 1,1,1 167 (72.9) 165 (62)* 112 (63.6)† 53 (58.9)‡
Type 1,1,0 14 (6.1) 22 (8.3) 16 (9.1) 6 (6.7)
Type 1,0,1 14 (6.1) 29 (10.9) 20 (11.4) 9 (10.0)
Type 0,1,1 24 (10.5) 41 (15.4) 26 (14.8) 15 (16.7)
Type 1,0,0 0 (0) 6 (2.3)* 2 (1.1) 4 (4.4)§
Type 0,1,0 2 (0.9) 3 (1.1) 0 (0) 3 (3.3)
Type 0,0,1 8 (3.5) 0 (0)¶ 0 (0)# 0 (0)
Calciﬁcation
Main branch 38 (16.6) 40 (15.0) 26 (14.8) 14 (15.6)
Side branch 12 (5.2) 13 (4.9) 8 (4.5) 5 (5.6)
Angulation
Y type (70°) 185 (80.8) 251 (94.4)** 170 (96.6)†† 81 (90)‡,
T type (70°) 44 (19.2) 15 (5.6)** 6 (3.4)†† 9 (10)†,
Values are presented as n (%). *p 0.05 forMC versus T-prov;†p 0.05 forMC versus T-prov 1-stent;‡p 0.05 forMC versus T-prov 2-stent;§p 0.01 forMC versus T-prov 2-stent; p 0.05 for T-prov 1-stent
versus T-prov 2-stent; ¶p 0.01 for MC versus T-prov; #p 0.01 for MC versus T-prov 1-stent; **p 0.001 for MC versus T-prov; ††p 0.001 for MC versus T-prov 1-stent.DB diagonal branch; LAD left anterior descending artery; LCX left circumflex artery; OM obtuse marginal; PL posterolateral; RCA right coronary artery; other abbreviations as in Table 1.Table 3. Procedural Details
Mini-Crush
(n  229 Lesions)
T-Prov
Overall
(n  266 Lesions)
1-Stent
(n  176 Lesions)
2-Stent
(n  90 Lesions)
Procedure
Kissing balloon pre-procedure 207 (90.4) 131 (49.2)* 104 (59.1)† 27 (30.0)‡§
Jailed wire technique 179 (78.2) 107 (40.2)* 66 (37.5)† 41 (45.6)‡
Kissing balloon after stent implantation 202 (88.2) 193 (72.6)* 146 (83) 47 (52.2)‡§
Post-dilatation of main branch 16 (6.9) 40 (15.0) 13 (7.3) 27 (33.3)‡§
Mean number of stents in main vessel 1.33 0.47 1.36 0.50 1.42 0.50 1.23 0.50
Mean number of stents in side vessel 1.31 0.46 1.01 0.11* — 1.01 0.11‡
Stent implantation
Only SES 138 (60.3) 139 (52.3) 102 (58) 37 (41.1)¶#
Only PES 57 (24.9) 90 (33.8)** 74 (42)† 16 (17.8)§
PES and SES 34 (14.8) 37 (13.9) — 37 (41.1)‡
Total stent length
Main 29.83 13.08 29.48 13.36 31.01 13.83 26.50 11.91#††
Side 18.41 7.49 18.46 7.46 — 18.46 7.46
Stent diameter
Main 2.89 0.33 2.86 0.40 2.83 0.42 2.93 0.34‡‡
Side 2.55 0.27 2.54 0.32 — 2.54 0.32
Values are presented as mean SD or n (%). Dashes indicate data are not available. *p 0.001 for MC versus T-prov; †p 0.001 for MC versus T-prov 1-stent; ‡p 0.001 for MC versus T-prov 2-stent; §p
0.001 for T-prov 1-stent versus T-prov 2-stent; p 0.01 for MC versus T-prov; ¶p 0.01 for MC versus T-prov 2-stent; #p 0.01 for T-prov 1-stent versus T-prov 2-stent; **p 0.05 for MC versus T-prov;
††p  0.05 for MC versus T-prov 2-stent; ‡‡p  0.05 for T-prov 1-stent versus T-prov 2-stent.PES paclitaxel-eluting stent; SES sirolimus-eluting stent; other abbreviations as in Table 1.
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190roup, and 14 in the T-prov 2-stent group. There were 2 cases
f multifocal and 3 of edge restenosis at the side and main
ranches in the T-prov 2-stent patients. There were also 24
ases of segment restenosis: 6 in the main branch of T-prov
atient groups, and 6 in the side branch of all patients groups.
After adjusting for the baseline differences between the MC
nd T-prov 1-stent groups using propensity score, treatment
ype was a significant predictor of main and side branch
estenosis at 9-month angiographic follow-up (hazard ratio
HR]: 0.52, 95% confidence interval [CI]: 0.27 to 0.99; p 
.047, and HR: 0.41, 95% CI: 0.20 to 0.85; p  0.016,
espectively). Conversely, TBR, TLR, and long-term cumula-
ive MACE were similar between the 2 groups (Fig. 1).
After adjusting for the baseline differences among the
C and both T-prov groups using propensity score, treat-
ent type was a significant predictor of side branch reste-
osis at 9-month angiographic follow-up (HR: 0.55, 95%
I: 0.37 to 0.82; p  0.004) (Fig. 2). Conversely, TBR,
LR, and long-term cumulative MACE were similar be-
ween the 2 groups.
iscussion
he best treatment for bifurcation lesions has not been
stablished yet. In the absence of proven efficacy of dedi-
Table 4. Clinical and Angiographic Outcome
Mini-Crush
(199 Patients, 229 Lesions) (258 Pati
Angiographic success
Main vessel 164 (71.6)
Side branch 180 (78.6)
Periprocedure MI 0
In-hospital MACE 0
30-day MACE 2 (1.0)
Cumulative MACE at follow-up 41 (20.6)
CABG 0
TVR non-TLR 4/160 (2.5) 1
TLR 30/188 (16.0) 46
TBR 16/188 (8.5) 32
Acute thrombosis 0
Subacute thrombosis 2 (1.0)
Late thrombosis 2 (1.0)
MI 4 (2.0)
Cardiac death 7 (3.5)
Noncardiac death 1 (0.5)
Main restenosis 22/188 (11.7) 37
Side restenosis 16/188 (8.5) 44
Values are presented as n (%). *p 0.01 for MC versus T-prov; †p 0.001 for MC versus T-prov 1-ste
2-stent; ¶p 0.05 for T-prov 1-stent versus T-prov 2-stent; #p 0.001 for MC versus T-prov; **p
MACEmajor adverse cardiac events; TBR target bifurcation revascularization; TLR target lated devices, drug-eluting stents and various techniques, penerally divided into 2 basic strategies with or without side
ranch stenting, are generally used to treat patients with
ifurcation lesions (12,18). Because some recent random-
zed studies of stenting of both branches failed to demon-
trate superiority over main vessel stenting and balloon
ilatation with provisional stenting of the side branch
6–8), the routine usage of 2 stents is actually not recom-
ended. However, the Colombo trial utilizing sirolimus-
luting stents is difficult to interpret, as the number of
atients is limited and there was a very high crossover rate
rom simple to complex strategy (6). The CORPAL (Drug-
luting Stents for Complex Lesions: Randomized Rapamy-
in Versus Paclitaxel) trial is also dealing with a limited
umber of cases and the complex strategy was performed
ith a technique that did not have much success when it
mployed T-prov but not as double-stent intention-to-treat
echnique (7). The Nordic trial considered as the end point
f an angiographic diameter stenosis 50% of the main
essel or an occlusion of the side branch. Indeed, in this
eries, restenosis rate in the side branch was significantly
igher in the group using a simple strategy (19.2%) as
ompared with those of using a complex strategy (10.9%)
8). Furthermore, as recently stated, it could be impossible
o do randomized trials in bifurcation lesions as each
atient’s anatomy may favor a particular technique, but trial
T-Prov
ll
66 Lesions)
1-Stent
(170 Patients, 176 Lesions)
2-Stent
(88 Patients, 90 Lesions)
6.3) 137 (77.8) 66 (73.3)
5.4)* 112 (63.6)† 62 (68.9)
.8) 2 (1.2) 0
.7)‡ 4 (2.4)§ 3 (3.4)
.7) 4 (2.4) 3 (3.4)
6.0) 44 (25.9) 23 (26.1)
.2) 0 3 (3.4)¶
.5) 0 1/69 (1.4)
2.2) 28/138 (20.3) 18/69 (26.1)
5.5)‡ 20/138 (14.5) 12/69 (17.4)
.4) 0 1 (1.1)
.1) 2 (1.1) 1 (1.1)
.5) 4 (2.3) 0
.4) 10 (5.8) 4 (4.5)
.8) 12 (7.1) 3 (3.4)
0 0
7.9) 24/138 (17.4) 13/69 (18.8)
1.2)# 26/138 (18.8)** 18/69 (26)††
0.05 for MC versus T-prov; §p 0.05 for MC versus T-prov 1-stent; p 0.05 for MC versus T-prov
r MC versus T-prov 1-stent; ††p 0.001 for MC versus T-prov 2-stent;
vascularization; TVR target vessel revascularization; other abbreviations as in Table 1.Overa
ents, 2
203 (7
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191emarkable subgroup of patients with bifurcation lesions
with larger side branches and/or large myocardium at risk
upplied by the side branch and/or more diseased vessels
nd/or with suboptimal result of the side branch) may be
reated with double stenting even if the intention is to try to
void it.
During the last few years, various researchers have tried to
nd alternative strategies to the crush technique, one of the
omplex techniques with higher safety profile on long-term
utcomes (19), but still with a significantly higher restenosis
ate at the side branch (20) despite the kissing balloon after
tenting, which is mandatory to reduce side branch reste-
Table 5. Quantitative Coronary Angiographic Analysis
Mini-Crush
(n  188 Lesions)
O
(n  2
Main branch
Baseline
Lesion length 22.00 10.29 16.4
RVD, mm 2.48 0.58 2.5
MLD, mm 0.96 0.45 1.0
DS % 62 12 5
After procedure
RVD, mm 3.03 0.55 2.9
MLD, mm 2.35 0.55 2.3
DS % 24 11 2
AG, mm 1.41 0.52 1.3
Follow-up
RVD, mm 2.76 0.51 2.6
MLD, mm 1.95 0.62 1.8
Restenosis, % 30 15 3
LLL, mm 0.42 0.65 0.4
Side branch
Baseline
Lesion length 9.25 8.07 7.4
RVD, mm 2.14 0.56 2.0
MLD, mm 1.14 0.61 1.1
DS % 48 14 4
After procedure
RVD, mm 2.59 0.55 2.2
MLD, mm 2.02 0.61 1.6
DS % 23 9 2
AG, mm 0.91 0.60 0.5
Follow-up
RVD, mm 2.29 0.64 2.0
MLD, mm 1.68 0.69 1.3
Restenosis, % 28 13 3
LLL, mm 0.39 0.68 0.3
Values are presented asmean SD. *p 0.001 forMC versus T-prov; †p 0.001 forMC versus T-pro
T-prov 1-stent; ¶p 0.01 for MC versus T-prov; #p 0.01 for MC versus T-prov 1-stent; **p 0.0
1-stent versus T-prov 2-stent; §§p 0.01 for MC versus T-prov 2-stent.
AG acute gain; DS diameter stenosis; LLL late luminal loss; MLDminimal lumen diametosis, is performed (21,22). Recently, Jim et al. (10) has meported a modified approach of the crush technique. Using
he so-called sleeve technique, these investigators split the
nal kissing balloon inflation into 2, so that the wire and
alloon have to cross only 1 layer of stent struts at every
ime. Although, this approach has the advantage of avoiding
anipulation or positioning of 2 bulky stents simulta-
eously, it has the drawback of being a more cumbersome
nd likely prolonged procedure. In many aspects this tech-
ique is similar to the “step crush technique” that Colombo
t al. (23) have described in the past with a main difference
ue to the performance of recrossing, balloon inflations, and
issing inflations before the implantation of a stent into the
T-Prov
sions)
1-Stent
(n  138 Lesions)
2-Stent
(n  69 Lesions)
42* 17.12 8.64† 15.11 7.86‡
60 2.50 0.67 2.53 0.42
47§ 1.09 0.46 1.02 0.51
¶ 57 11† 58 22
45 2.92 0.47 3.04 0.40
40 2.29 0.41 2.37 0.38
22 10 22 12
51 1.37 0.51 1.35 0.49
43 2.62 0.44# 2.80 0.40**
51 1.85 0.51 1.96 0.50
30 13 30 16
54 0.44 0.53 0.41 0.56
22 7.25 5.82 7.80 3.82
52 2.05 0.52 2.00 0.52
46 1.20 0.47 1.16 0.46
* 4214† 41 24††
45* 2.14 0.34† 2.54 0.53‡‡
52* 1.55 0.45† 1.92 0.56‡‡
* 29 10† 23 13**
55* 0.41 0.45† 0.75 0.65‡‡
54* 1.98 0.61† 2.22 0.32**
42* 1.23 0.36† 1.47 0.49††‡‡
¶ 38 11† 34 17§§
54 0.22 0.49 0.45 0.61**
nt; ‡p 0.001 forMC versus T-prov 2-stent; §p 0.05 forMC versus T-prov; p 0.05 forMC versus
rov 1-stent versus T-prov 2-stent; ††p 0.05 for MC versus T-prov 2-stent; ‡‡p 0.001 for T-prov
 reference vessel diameter; other abbreviations as in Table 1.verall
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192ianos et al. (24), by Lim et al. (25), and more extensively
n the study by Galassi et al. (9), where the MC technique
escribed is a further refinement of the previous 2 ap-
roaches. Using this technique, which consists of crushing
he 1- to 2-mm proximal side branch stent by a balloon
nstead of crushing the 3- to 4-mm proximal side branch
tent by another stent, as in the standard crush technique,
alassi et al. (9) showed excellent in-hospital outcomes
ith low MACE and restenosis rates especially at the side
ranch in a pilot study. Following this approach it seems
hat there is less risk that the main-vessel stent will be
eformed and potentially unopposed to the vessel wall and
hus predisposed to restenosis or stent thrombosis of the
ide branch, as is further suggested by Ormiston and
olleagues by bench studies (26,27).
Employing this MC technique in a consecutive series of
atients with bifurcation lesions, the results of this study
howed that this 2 drug-eluting stent technique provides
xcellent long-term outcomes and rates of MACE at
ong-term follow-up similar to those obtained by the
-prov approach using a single or a double stent. Similar
ates of acute, subacute, and late thrombosis are found
ollowing the 2 different treatment strategies. The overall
esults obtained by the MC technique of a TLR of 16.0%,
BR of 8.5%, main branch restenosis of 11.7%, and side
ranch restenosis of 8.5% confirmed the results previously
btained in a small pilot study by Galassi et al. (9) where
LR was 12.2%, TBR 4.1%, main branch restenosis 12.2%,
Figure 1. Clinical and Angiographic Outcome After Adjustment for
Propensity Score
Hazard ratios for MACE, TLR, TBR, and restenosis with mini-crush technique
and T-prov 1-stent technique. Hazard ratios are shown in a logarithmic
scale and signiﬁcant values are expressed in the text. MACE  major
adverse cardiac events; MI  myocardial infarction; TBR  target bifurca-
tion revascularization; TLR  target lesion revascularization; T-prov 
T-provisional; TVR  target vessel revascularization.nd side branch restenosis 2.0%.Moreover, after adjusting for baseline differences between
he MC and T-prov 1-stent groups using propensity score
C technique was found to provide significantly lower
ain and side branches restenosis, while when after adjust-
ng for baseline differences between the MC and both
-prov groups using propensity score, main branch reste-
osis lost significance albeit small.
omparison with previous studies. The overall T-prov TLR
ate (22.2%) is higher than the rate previously reported in
ther studies (Table 6) (6–9,13,19–21,28). This was pri-
arily due to a higher restenosis rate of the side branch as
as recently shown in the Nordic study where restenosis
ate at the side branch was 26.4% (8); however, in this
revious study, the TLR rate remained extremely low
1.9%), mainly because the primary angiographic end point
as restenosis in the main vessel or occlusion of the side
ranch. In our studies, potential differences include the
onger duration of clinical follow-up (9 vs. 6 months) and
he higher rate of assessing patients using stress test or
unctional imaging tests after procedure and treatment of
ilent ischemia. Indeed, following up this approach, 61
esions in 93 cases of restenosis (65.6%) in our patients were
reated as compared with only 7 of 17 (41%) in the
olombo study (6), 5 of 10 (50%) in the Tanabe study (27),
nd 4 of 36 (11%) of the Nordic study (8). Finally, in the
tudy of Pan et al. (13), only 50% of patients completed the
ngiographic follow-up, thus reducing potential number of
LR and silent restenosis rate even further.
tudy limitations. This study has some limitations due to its
etrospective nature. The most important is the lack of
andomization with regard to stenting strategy left to the
Figure 2. Clinical and Angiographic Outcome After Adjustment for
Propensity Score
Hazard ratios for MACE, TLR, TBR, and restenosis with mini-crush technique
and both T-prov technique groups. Hazard ratios are shown in a logarith-
mic scale and signiﬁcant values are expressed in the text. Abbreviations as
in Figure 1.
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193perator’s discretion. However, as pointed out by a recent
ocument of consensus, randomized trials are difficult to
arry out because each patient’s anatomy may favor a
articular technique, but trial patients overall will be heter-
geneous (12). Furthermore, we cannot exclude a selection
ias due to treatment unbalance among the surgeons.
Although the study consisted of a consecutive group of
atients who all had routine angiographic follow-up and in
ll cases the stringent criteria of the MC technique or
-prov approach were used, it only reflected the experience
f a single institution.
onclusions
oth techniques of bifurcation treatment met high proce-
ural success with low complication rates and similar
ACE long-term outcomes. However, the MC technique,
double-stent intention-to-treat technique, yields a lower
estenosis rate at side branches when compared with the
-prov technique. These results may confirm the advantage
f using a pre-scheduled 2-stent technique to give complete
overage of the side branches’ ostium as compared with a
rovisional technique whether or not a second bail-out stent
s needed.
eprint requests and correspondence: Prof. Alfredo R. Galassi,
ia Antonello da Messina 75, Acicastello, 95021, Catania, Italy.
-mail: argalassi@virgilio.it.
Table 6. Comparison of Present Study With Other Published Work
Authors (Ref. #) Publication, Year Randomized Tech
Colombo et al. (6) Circulation, 2004 Yes T-prov
Crush
Pan et al. (7) Am Heart J, 2004 Yes T-prov
Mixed
Tanabe et al. (28) Am J Cardiol, 2004 No Mixed
Ge et al. (21) J Am Coll Cardiol, 2005 No Crush
Steigen et al., for
Nordic (8)
Circulation, 2006 Yes T-prov
Crush
Moussa et al. (19) Am J Cardiol, 2006 No Crush
Hoye et al. (20) J Am Coll Cardiol, 2006 No Crush
Pan et al. (13) Am Heart J, 2007 No T-prov
Galassi et al. (9) Catheter Cardiovasc
Interv, 2007
No MC
Galassi et al. Present study No T-prov
T-prov
MC
MBmain branch; SB side branch; other abbreviations as in Tables 1 and 4.EFERENCES
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APPENDIX
or propensity score and sensitivity analyses, please see the online version
f this article.
